Poorly controlled respiratory conditions can diminish productivity at the level of individuals, households, employers and the broader economy
India’s growth story is often told through numbers: the size of its workforce, the strength of its demographic dividend, and the pace of its economic expansion. Yet, behind every economic statistic is a human reality.
The true measure of a nation’s progress is not only how many people it has of working age, but how many can remain healthy and active through their most productive years. Human capital is ultimately built on human capability, and capability begins with health.
Lung health, therefore, deserves a prominent place in India’s growth conversation.
Breathing is the most fundamental act of life. Yet, we rarely think about it until it becomes a struggle. For millions of Indians living with respiratory conditions, that challenge is a daily reality. The impact extends far beyond hospitals or clinics. It is felt in factories, offices, farms, classrooms, homes, and small businesses where breathlessness, fatigue, and recurring symptoms erode productivity, livelihood, and quality of life.
India already carries a substantial burden of respiratory diseases, which in 2023 accounted for 31.2 million disability-adjusted life years in India, representing 43.3 per cent of Asia’s chronic respiratory disease burden. The economic impact extends beyond medicines and hospitalisation. Poorly controlled respiratory conditions can affect an individual’s ability to work, remain physically active and participate fully in daily life.
India’s demographic dividend is often described in terms of age, scale and workforce participation. But its real value depends on how many people are healthy enough to contribute consistently through their most productive years. And respiratory health is central to this equation. Chronic breathlessness, recurring exacerbations, and reduced physical capacity may not always remove people from the workforce, but they can significantly affect how they perform. Over time, these limitations can diminish productivity at the level of individuals, households, employers and the broader economy.
The question, therefore, is not only what respiratory disease costs to treat, but also what the nation stands to lose when millions of people are unable to operate at their full capacity. Viewed through this lens, lung health becomes not just a medical issue but also a critical economic one.
The economic burden of respiratory disease is often underestimated because visible healthcare costs capture only part of the impact. A large share of the burden sits outside the healthcare system in the form of missed workdays, reduced performance, repeated caregiver absence and the gradual loss of productive capacity.
As healthcare evolves, the conversation must move beyond managing acute episodes to enabling sustained disease control and long-term outcomes. For the pharmaceutical industry, this means focusing equally on treatment availability as well as education, adherence support, correct device use and continuity of care.
Economic growth and public health are often discussed separately. In reality, they are deeply interconnected. The economic cost of poor lung health is often felt much before a hospital admission. It is seen in the worker who performs below capacity, the caregiver who misses work, and the household that absorbs the financial and emotional strain of repeat illness. These costs may not appear in healthcare budgets, but they matter deeply to India’s productivity story.
This Op-ed was first published in The Hindu Business Line (print and online) dated November 16, 2026